We take an open, honest and transparent approach to how we work together.
Three guiding principles shape how we work
Clarity
Flexibility
We commit to doing the right thing, reacting to the changes as they happen, and delivering what is needed – not only what is asked for.
Value
We focus on addressing your most difficult challenges – shaping your thinking and guiding your actions.
We balance client focus with technical expertise
We wrap a dedicated, multi-disciplinary team around each of our clients – allowing them to speak your language, share in your strategic priorities and foresee the next wave of challenges before they arrive.
To deliver the innovative solutions needed, these teams are supported by three technical pillars of expertise:
Product and organisational strategy.
Define internal and external processes and plans to develop product and portfolio differentiation that meet stakeholder needs.
Example solutions: Gap analysis & mitigation planning / Payer requirements mapping / Early economic modelling / Value proposition development / Competitor price benchmarking / Consensus generation (Delphi panel) / Organisational audit & re-design
Health economics and evidence generation.
Build and refine data and evidence to maximise product value for all stakeholders.
Example solutions: BOI retrospective chart review / Phase 3 design optimisation / Systematic literature review / PRO design & testing / Cost-effectiveness analysis
Market access, medical and policy communications.
Communicate product value to maximise access and commercial success.
Example solutions: HTA preparation and submission / In-market value materials / Core value dossier / HEOR Publications
Our thinking
The best way to understand what we can do, is to understand how we think.
Below are our recent thought leadership articles, discussing some of the recent challenges facing our industry. Contact us if you would like to discuss any of these topics, or how we could support your specific challenges.
The meaning of Wickenstones
Combining innovation with real-world pragmatism, we tackle our client’s most challenging issues – focusing on the whole of the problem, not just a small part.
1
We ground our approaches and solutions in common sense and pragmaticism.
2
We gain and maintain internal alignment to strengthen implementation.
3
We apply fresh thinking to each new question or challenge we are faced with – never re-heating old ideas.
Wickenstones
Old English place name for a location where a rowan tree grows from a harsh and seemingly barren stone plateau.
The persistence of this tree to overcome the savage nature of its environment and to anchor itself deep into the crevasses within the rock represents the nature of our business – grounded in evidence and dedicated to overcoming the challenges that the environment presents us with.
The senior team at the heart of your projects
Eddie has over 20 years’ experience working across multiple geographies and senior roles within the industry. He has personally led several major European launches and the creation and implementation of global access plans in a wide range of therapy areas including oncology, haematology, virology, neuroscience, cardiovascular disease and diabetes. This has included leadership of several HTA submissions to NICE, the SMC and AWMSG across a diverse set of therapy areas as well as serving on the ABPI representation to both the SMC and NICE.
Dingeman holds a masters' in international health management from Imperial College London. He is a client lead with over 7 years of experience in market access & strategy, developing plans and solutions to support the development and launch of pharmaceutical assets. His experience includes clinical and payer advisory boards, HTA submissions (inc. PAS schemes), objection handlers, value proposition development, stakeholder engagement strategies, systematic literature reviews, brand management, organisational redesign, healthcare system landscaping, surveys inc. BoI studies, RWE and pricing research. Therapy areas include diabetes, obesity, NASH, oncology, neuromuscular disorders, cystic fibrosis, epilepsy and rare diseases such as SMA, XLH, SCD and OI.
James holds a PhD in investigative medicine from Imperial College London, and has over 8 years’ experience working on and managing strategic market access projects. This experience includes managing landscape assessments, literature reviews, value propositions, health economic models, pricing strategy, real-world evidence, advisory panels, publications and stakeholder engagement strategy. James has experience across a range of therapeutic areas, including infectious diseases, rheumatology, gastroenterology, cardiovascular disease, metabolic disease, women's health, oncology and orphan indications.
Ruairi has a PhD in Pharmacology and has spent the last 15 years’ working in market access & HEOR, across multiple geographies and senior roles. His experience covers value strategy and communication, strategic pricing, organisational design, HTA strategy and early pipeline planning. In addition, Ruairi has experience across a range of therapeutic areas including oncology, haematology, virology, neuroscience, cardiovascular disease and diabetes.
Alysia holds a PhD in genetics, and has over 5 years’ experience delivering market access, HEOR and communication projects for clients across the life sciences industry. As our Technical Lead for Market access, Medical & Policy Communications, Alysia brings deep expertise and know-how with respect to medical writing, communication strategy and literature reviews. Alysia has experience across a range of therapeutic areas, including orphan diseases, oncology, respiratory disease, neurodegenerative disease, metabolic disease, gene therapy and regenerative medicine.
Elsa brings extensive experience in both pharma as well as consulting, with a specialization in global market access and reimbursement planning. She held varied commercial positions within the pharmaceutical industry. For over 16 years, she specialized in developing reimbursement strategies for pipeline and commercialized assets in oncology, immunology, central nervous system, cardiology and renal diseases. In consulting, she led over 50 projects in a variety of areas, such as rare & orphan diseases, gene and cell therapy and evidence generation planning for CAR-T assets. She has led advisory boards, workshops and facilitated focus groups. A graduate of Princeton University, her academic training is in Public Policy.
Örjan has 12 years of HEOR consultancy experience specialising in health economics modelling and evidence generation/patient level data analysis. Expertise in the former include all the usual designs; cohorts, decision trees and simulations; as well as both early models, submission models and pricing tools in most major therapy areas. Örjan holds a PhD from the Royal institute of Technology and more recently performed a post-doc at Karolinska Institute, Stockholm.
John brings over 40 years biopharma experience with him to Wickenstones, having worked with bio pharma manufacturers in various senior level commercial /market access roles in both large and small, startup organizations. His experience includes specialty, ultra-rare orphan, infused, injectable, medical and pharmacy benefit products as well as multiple small molecule launches (he’s participated in over 30 new product launches). Therapeutic areas include oncology, cardiovascular, gastrointestinal, nephrology, pulmonary, rheumatology and more. John brings US expertise regarding commercial and public payers, distribution (third party logistics, specialty pharmacy and distributors), contracting and more. John has a BA in behavior science from the University of Massachusetts Amherst and has completed business graduate work at Boston College, Rockhurst University and Worcester Poly Tech.
Samantha has a background in medical writing, evidence generation, and systematic reviewing. She holds a PhD in molecular genetics and has experience across a range of disease areas including oncology, diabetes, inflammatory bowel disease, and rare inherited disorders.